C22
Conditions
Interventions
Group 1: Stage B HCC (Hepatocellular carcinoma) patients treated with TACE (Transcatheter Arterial Chemoembolization) and received dendritic cells as adjuvant therapy (Group I)
stage C or D advanced HCC patients received dendritic cells as a treatment (Group III)
Group 2: Stage B HCC patients treated with TACE only (Group II)
stage C or D advanced HCC patients received supportive treatment (Group IV).
Sponsors
Faculty of medicine-Tanta University
Eligibility
Sex/Gender
All
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: According to Barcelona Clinic Liver Cancer (BCLC) staging system, stage B HCC patients not fit for resection or local ablative therapies, stage C HCC patients with portal vein thrombosis and stage D HCC patients with lymphatic or distant metastases are included.
Exclusion criteria
Exclusion criteria: HCC patients (stage 0 and A) fit for radical or local ablation therapies or HCC patients with platelet count below 50,000 and or prothrombin activity below 50% were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| What? - Improvement in the clinical, laboratory and radiological characteristics of the tumour How? - Generation of dendritic cells from peripheral blood of each patient was performed. Dendritic cells were identified by CD 83, CD 86 expressions using flow cytometry. All patients included undergo a clinical, laboratory and radiological evaluation as Abdominal ultrasonography, and serum bilirubin, Alanine aminotransferase, Aspartate aminotransferase, albumin, International Normalized Ration, with estimation of the degree of ascites, encephalopathy and Child-Pugh Class When? - All of these clinical, laboratory and radiological investigations were performed before treatment (baseline) and after 1, 3 and 6 months of treatment (follow up). | — |
Countries
Egypt
Contacts
Public ContactDina Abdel Hai
Clinical pathology department-Faculty of medicine-Tanta University
Outcome results
None listed